Funding Digital Therapeutics – Who counts?

Digital therapeutics, when created empathetically to patients and health care professionals (HCPs), can show significant value to all stakeholders in the healthcare pathway [1]. A question at a recent NHS conference prompted an important question: if pharma is funding these innovations with a commercial motivation, how do you ensure equality in access to digital therapeutics?…

Evidence in Digital Therapeutics – Proof and Power

The key differentiator between ‘digital health and wellbeing technologies’ and ‘digital therapeutics’ is that the latter must show improved outcomes. Approximately 140 studies were published in 2017 which contained clinical evidence of digital health efficacy [1]. Clinically validated technologies have looked to show value for health systems by reducing emergency hospitalisation, A&E, ambulatory, drug and…

Highlights from NICE 2018 – Tackling Antimicrobial Resistance Globally and Locally

pH Associates were delighted to meet with current and former clients at the NICE Conference #NICEConf18 last week and to have the opportunity to attend some thought-provoking breakout sessions.  Of particular interest was a topical session focused on ‘Tackling Antimicrobial Resistance Globally and Locally’, with Nick Crabb (Programme Director, Scientific Affairs, NICE), Susan Hopkins (Chair…